论文部分内容阅读
目的 :重组干扰素α1b(赛若金 )和重组干扰素αⅡb(干扰能 )治疗慢性乙型肝炎疗效观察。方法 :治疗组 5 0例慢性乙型肝炎患者给予赛若金 3 0 0万单位 /天 ,15天后改为 3 0 0万单位 /隔天× 5个月治疗 ;对照组用干扰能治疗 ,其剂量、用法、疗程均同于赛若金组 ,其间定期检测肝功能、血清乙肝病毒标志、HBV -DNA、血常规及血清肝纤维化指标。结果 :治疗组和对照组在疗程结束时比较 ,HBeAg转阴率各为 43 %和 41%,HBV -DNA转阴率各为 5 1%和 48%,两组无显著差异。另外于疗程结束时 ,对赛若金治疗后的血清肝纤维化指标进行比较 ,其治疗前和治疗后HA各为 162 7± 68 5与 97 5± 43 3 ,Ⅳ -C各为 79 8± 3 6 7与 5 6 5±2 4 2 ,相比有显著差异 (P <0 .0 5 )。结论 :赛若金和干扰能相比具有疗效相仿、副反应低的优点。赛若金有抗肝纤维化疗效
Objective: To observe the curative effect of interferon α1b (recombinant human interferon α1b) and recombinant interferon α Ⅱ b (interfering energy) in the treatment of chronic. Methods: Fifty patients with chronic hepatitis B in the treatment group were given 300 million units per day and 15 days after the treatment to 30 million units / every other day for 5 months. In the control group, Dosage, usage, course of treatment were the same as the Saurin group, during which regular testing of liver function, serum hepatitis B virus markers, HBV-DNA, blood and serum liver fibrosis indicators. Results: At the end of the treatment period, HBeAg negative rates were 43% and 41% in treatment group and control group respectively, 51% and 48% in HBV-DNA negative rate respectively. There was no significant difference between the two groups. In addition, at the end of the course of treatment of saxophone serum hepatic fibrosis indicators were compared before and after treatment, HA each of 162 7 ± 68 5 and 97 5 ± 43 3, Ⅳ C each of 79 8 ± There was a significant difference between 3 6 7 and 5 6 5 ± 2 4 2 (P <0.05). Conclusion: Sauruojin compared with interference can have similar efficacy, low side effects. If race gold anti-liver fibrosis effect